Literature DB >> 8186044

Low content of estrogen receptors in human giant cell tumors of bone.

M Ishibe1, Y Ishibe, T Ishibashi, T Nojima, R N Rosier, J E Puzas, K Kaneda.   

Abstract

We tried to identify estrogen receptors (ERs) in human giant cell tumors of bone. Samples from eight patients were used for biochemical and immunohistochemical studies using [125I]17 beta-estradiol and monoclonal antibody against the human ER. Estradiol binding sites were detected in seven cases out of eight. The dissociation constant of the higher affinity binding site was 0.5 nM. Nonlabeled 17 beta-estradiol and synthetic estrogen, diethyl-stilbestrol, inhibited the binding of labeled 17 beta-estradiol to the tumor cytosol, while dexamethasone did not inhibit the binding. Using a monoclonal antibody. Western blotting identified bands of M(r) 68,000 and 59,000. No ERs were observed in any case examined immunohistochemically. These results suggest that human giant cell tumors of bone have a low level of ERs that cannot be detected immunohistochemically.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8186044     DOI: 10.1007/bf00572916

Source DB:  PubMed          Journal:  Arch Orthop Trauma Surg        ISSN: 0936-8051            Impact factor:   3.067


  16 in total

1.  A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.

Authors:  M M Bradford
Journal:  Anal Biochem       Date:  1976-05-07       Impact factor: 3.365

2.  Estrogen receptor protein in bone and soft tissue tumors.

Authors:  S W Weiss; J M Langloss; B M Shmookler; M M Malawer; J D'Avis; F M Enzinger; R Stanton
Journal:  Lab Invest       Date:  1986-06       Impact factor: 5.662

Review 3.  Steroid receptors and giant cell tumor of bone.

Authors:  L E Wold; T Spelsberg; N Jiang; F Sim
Journal:  Curr Top Pathol       Date:  1989

4.  Estrogen receptor in a human cell line (MCF-7) from breast carcinoma.

Authors:  S C Brooks; E R Locke; H D Soule
Journal:  J Biol Chem       Date:  1973-09-10       Impact factor: 5.157

5.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

6.  Inactivation of oestrogen receptor in vitro by nuclear dephosphorylation.

Authors:  F Auricchio; A Migliaccio; A Rotondi
Journal:  Biochem J       Date:  1981-02-15       Impact factor: 3.857

Review 7.  Characterization of cells from human giant cell tumors of bone.

Authors:  S R Goldring; A L Schiller; H J Mankin; J M Dayer; S M Krane
Journal:  Clin Orthop Relat Res       Date:  1986-03       Impact factor: 4.176

8.  Rapid purification of the estrogen receptor by sequence-specific DNA affinity chromatography.

Authors:  F V Peale; Y Ishibe; C M Klinge; S Zain; R Hilf; R A Bambara
Journal:  Biochemistry       Date:  1989-10-31       Impact factor: 3.162

9.  Fluorescent histochemical demonstration of estrogen and progesterone binding in giant cell tumors of bone: preliminary observations.

Authors:  M Malawer; M Bray; M Kass
Journal:  J Surg Oncol       Date:  1984-03       Impact factor: 3.454

10.  Comparison of immunocytochemical and steroid-binding assays for estrogen receptor in human breast tumors.

Authors:  W J King; E R DeSombre; E V Jensen; G L Greene
Journal:  Cancer Res       Date:  1985-01       Impact factor: 12.701

View more
  2 in total

1.  17 beta-estradiol increases the receptor number and modulates the action of 1,25-dihydroxyvitamin D3 in human osteosarcoma-derived osteoblast-like cells.

Authors:  M Ishibe; T Nojima; T Ishibashi; T Koda; K Kaneda; R N Rosier; J E Puzas
Journal:  Calcif Tissue Int       Date:  1995-12       Impact factor: 4.333

2.  A rare thoracic intraspinal schwannoma in twin pregnancy with aggravated clinical presence: A case report following CARE.

Authors:  Ruiqi Chen; Anqi Xiao; Lu Xing; Chao You; Jiagang Liu
Journal:  Medicine (Baltimore)       Date:  2017-03       Impact factor: 1.889

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.